Research Program: Carcinogenesis & Chemoprevention
Assistant Professor, Department of Medicinal Chemistry, College of Pharmacy

xingx009@umn.edu
612-626-5675 — office phone
612-626-5543 — lab phone
Preferred contact method: e-mail

Biographical information

• B.S. Dalian University of Technology, 1996
• Ph.D. Arizona State University, 2001
• Postdoc. Harvard University, 2003

Research Interests

1. Develop chemopreventive agents from dietary and synthetic sources
2. Develop chemotherapeutic agents targeting apoptotic pathways
3. Explore mechanisms of action and study cell death pathways

For a more detailed description of Dr. Xing's research interests, please visit his Department of Medicinal Chemistry profile.

Selected Publications

Wang L, Kong F, Xing C. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg. Med. Chem. Lett. 2008;18:236-240.

Tian D, Das SGK, Doshi J, Peng J, Lin J, Xing C. sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell. Cancer Lett. 2008;259:198-208.

Doshi J, Tian D, Xing C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against anti-apoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species (ROS) that induce apoptosis. Mol Pharm. 2007;4: 919-928.

Wang L, Tang X, Sham Y, Xing C. Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1. Bioorg Med Chem. 2007;15: 2167-2176.

Doshi J, Tian D, Xing C. Structure-activity relationship studies of HA 14-1 — an antagonist for anti-apoptotic Bcl-2 proteins to overcome drug resistance in cancer. J Med Chem. 2006;49:7731-7739.

Xing C, LaPorte J R, Barbay JK, Myers AG. Identification of GAPDH as a protein target of the saframycin class of natural antiproliferative agents. Proc Natl Acad Sci. USA, 2004;101:5862-5866.